Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas

Neuro-Oncology

Volumn 13, Issue 2, 2011, Pages 203-211

  Weyerbrock, Astrid ^a,b   Walbridge, Stuart ^b   Saavedra, Joseph E ^d   Keefer, Larry K ^c   Oldfield, Edward H ^b,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Blood brain barrier permeability; Cerebral blood flow; Glioma; Nitric oxide; Quantitative autoradiography (QAR)

Indexed keywords

2 AMINO 2 METHYLPROPIONIC ACID; 6 ANILINO 5,8 QUINOLINEQUINONE; 8 BROMOGUANOSINE PHOSPHATE; AMINOGUANIDINE; CARBON 14; CYCLIC GMP; DEXAMETHASONE; DISODIUM 1 [2 (CARBOXYLATO)PYRROLIDIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE METHANOLATE; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; IODOPHENAZONE; METHYLPREDNISOLONE; NITRIC OXIDE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; BRAIN BLOOD FLOW; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLIOMA; HUMAN; ISOTOPE LABELING; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; TUMOR BLOOD FLOW;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; BRONCHODILATOR AGENTS; CAPILLARY PERMEABILITY; CEREBROVASCULAR CIRCULATION; GLIOMA; GUANOSINE; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; PHOSPHODIESTERASE INHIBITORS; PROLINE; PURINONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79951828763     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq161     Document Type: Article

References (48)

1. Lam-Himlin D, Espey MG, Perry G, Smith MA, Castellani RJ. Malignant glioma progression and nitric oxide. Neurochem Int. 2006;49:764-768. (Pubitemid 44648494)
2. Ridnour LA, Thomas DD, Donzelli S, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal. 2006;8:1329-1337. (Pubitemid 44182431)
3. Wink DA, Mitchell JB. Nitric oxide and cancer: an introduction. Free Radic Biol Med. 2003;34:951-954. (Pubitemid 36398555)
4. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995;55:727-730.
5. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol. 1992;107:1092-1095.
6. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N (G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol. 1999;155:1381-1390. (Pubitemid 29488945)
7. Maeda H, Akaike T, Yoshida M, Suga M. Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. J Leukoc Biol. 1994;56:588-592. (Pubitemid 24348817)
8. Swaroop GR, Malcolm GP, Kelly PA, Ritchie I, Whittle IR. Effects of nitric oxide modulation on tumour blood flow and microvascular permeability in C6 glioma. Neuroreport. 1998;9:2577-2581. (Pubitemid 28387152)
9. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery. 1996;39:125-133.
10. Mitchell JB, Cook JA, Krishna MC, et al. Radiation sensitisation by nitric oxide releasing agents. Br J Cancer Suppl. 1996;27:S181-S184. (Pubitemid 26237957)
11. Bartus RT, Snodgrass P, Marsh J, et al. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival [In Process Citation]. J Pharmacol Exp Ther. 2000;293:903-911. (Pubitemid 30417857)
12. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res. 1996;56:4027-4031. (Pubitemid 26284755)
13. Prados MD, Schold SJS, Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carbo-platin administered intravenously for the treatment of recurrent malignant glioma. Neurooncology. 2003;5:96-103. (Pubitemid 36416838)
14. Keefer LK. Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates. Annu Rev Pharmacol Toxicol. 2003;43:585-607. (Pubitemid 37372654)
15. Shami PJ, Saavedra JE, Wang LY, et al. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic a Activity. Mol Cancer Ther. 2003;2:409-417.
16. Kapadia MR, Chow LW, Tsihlis ND, et al. Nitric oxide and nanotechnol-ogy: a novel approach to inhibit neointimal hyperplasia. J Vasc Surg. 2008;47:173-182.
17. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg. 1997;87:746-751. (Pubitemid 27454594)
18. Pluta RM, Rak R, Wink DA, et al. Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury. Neurosurgery. 2001;48:884-892; discussion 892-883.
19. Saavedra JE, Southan GJ, Davies KM, et al. Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor. J Med Chem. 1996;39:4361-4365. (Pubitemid 26359392)
20. Weyerbrock A, Walbridge S, Pluta RM, et al. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg. 2003;99:728-737. (Pubitemid 37159051)
21. Mayhan WG. Regulation of blood-brain barrier permeability. Microcirculation. 2001;8:89-104. (Pubitemid 33600462)
22. Groothuis DR, Fischer JM, Pasternak JF, et al. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Cancer Res. 1983;43:3368-3373. (Pubitemid 13032642)
23. Groothuis DR, Pasternak JF, Fischer JM, et al. Regional measurements of blood flow in experimental RG-2 rat gliomas. Cancer Res. 1983;43:3362-3367. (Pubitemid 13061598)
24. Sakurada O, Kennedy C, Jehle J, Brown JD, Carbin GL, Sokoloff L. Measurement of local cerebral blood flow with iodo [14C] antipyrine. Am J Physiol. 1978;234:H59-H66. (Pubitemid 9174482)
25. Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR. Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol. 1986;19:50-59. (Pubitemid 16137980)
26. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 1998;58:159-165. (Pubitemid 28027731)
27. Hamalainen M, Lilja R, Kankaanranta H, Moilanen E. Inhibition of iNOS expression and NO production by anti-inflammatory steroids. Reversal by histone deacetylase inhibitors. Pulm Pharmacol Ther. 2008;21:331-339. (Pubitemid 351312675)
28. Chi OZ, Liu X, Weiss HR. Effects of cyclic GMP on microvascular permeability of the cerebral cortex. Microvasc Res. 1999;58:35-40. (Pubitemid 29390223)
29. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 2002;200:639-646. (Pubitemid 34823055)
30. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol. 2004;108:43-48. (Pubitemid 38961072)
31. Yin D, Wang X, Konda BM, et al. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin Cancer Res. 2008;14:4002-4009.
32. Sugita M, Hunt GE, Liu Y, Black KL. Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin. Neurol Res. 1998;20:559-563. (Pubitemid 28367271)
33. Waterhouse DJ, Saavedra JE, Davies KM, et al. Injectable formulation of disodium 1-[2-(carboxylato) pyrrolidin-1-yl]diazen-1-ium-1, 2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug. J Pharm Sci. 2006;95:108-115.
34. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498-1505. (Pubitemid 38004777)
35. Boje KM, Jaworowicz D, Jr, Raybon JJ. Neuroinflammatory role of pros-taglandins during experimental meningitis: evidence suggestive of an in vivo relationship between nitric oxide and prostaglandins. J Pharmacol Exp Ther. 2003;304:319-325. (Pubitemid 36008944)
36. Candelario-Jalil E, Taheri S, Yang Y, et al. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther. 2007;323:488-498. (Pubitemid 350005134)
37. Davis TW, Zweifel BS, O'Neal JM, et al. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther. 2004;308:929-934. (Pubitemid 38263967)
38. Shapiro WR, Hiesiger EM, Cooney GA, et al. Temporal effects of dexa-methasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma. J Neurooncol. 1990;8:197-204. (Pubitemid 20213293)
39. Molnar P, Lapin GD, Groothuis DR. The effects of dexamethasone on experimental brain tumors: I. Transcapillary transport and blood flow in RG-2 rat gliomas. J Neurooncol. 1995;25:19-28.
40. Heiss JD, Papavassiliou E, Merrill MJ, et al. Mechanism of dexametha-sone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest. 1996;98:1400-1408. (Pubitemid 26322065)
41. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocor-ticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA. 1992;89:3917-3921.
42. Portnow J, Suleman S, Grossman SA, Eller S, Carson K. A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neurooncology. 2002;4:22-25. (Pubitemid 34269463)
43. Gu YT, Zhang H, Xue YX. Dexamethasone enhances adenosine 5'-triphosphate-sensitive potassium channel expression in the blood-brain tumor barrier in a rat brain tumor model. Brain Res. 2007;1162:1-8. (Pubitemid 47088369)
44. Ningaraj NS, Rao MK, Black KL. Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res. 2003;63:8899-8911. (Pubitemid 38064070)
45. Fross RD, Warnke PC, Groothuis DR. Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research. J Neurooncol. 1991;11:185-197.
46. Barth RF, Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 2009;94:299-312.
47. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multi-center study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647. (Pubitemid 30056941)
48. Tozer GM, Prise VE, Chaplin DJ. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res. 1997;57:948-955. (Pubitemid 27098023)